PT  - JOURNAL ARTICLE
AU  - ONDREJ FIALA
AU  - MILOS PESEK
AU  - JINDRICH FINEK
AU  - MAREK MINARIK
AU  - LUCIE BENESOVA
AU  - ONDREJ SOREJS
AU  - MARTIN SVATON
AU  - ZBYNEK BORTLICEK
AU  - RADEK KUCERA
AU  - ONDREJ TOPOLCAN
TI  - Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC
DP  - 2016 Jan 01
TA  - Anticancer Research
PG  - 455--460
VI  - 36
IP  - 1
4099  - http://ar.iiarjournals.org/content/36/1/455.short
4100  - http://ar.iiarjournals.org/content/36/1/455.full
SO  - Anticancer Res2016 Jan 01; 36
AB  - Background: Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. Patients and Methods: The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively. Results: EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed. Conclusion: EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.